Neoplasms

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Infections

Rare Diseases

Lymphoma

Lymphoma, T-Cell

Lymphoma, T-Cell, Peripheral

Mycoses

Mycosis Fungoides

Lymphoma, T-Cell, Cutaneous

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Lymphoma, Non-Hodgkin

Lymphosarcoma

Peripheral T-cell Lymphoma

Cutaneous T-cell Lymphoma

Forodesine 200 mg

Nashat Gabrail, MD

Madeleine Duvic, MD

Youn Kim, MD

Andres Forero-Torres, M.D.

Alan B Fleischer, Jr., MD

Gary S. Wood, MD

Andre Goy, MD

Larisa Geskin, MD

Nancy Bartlett, MD

Francine Foss, MD

Miles Prince, MD

Elise Olsen, MD

Sareeta S Parker, MD

Neil J Korman, MD, PhD

Francesco Turturro, MD

Andrei R Shustov, MD

This is a Phase II, non-randomized, open-label, single-arm trial that will be conducted at up to 50 sites in North America, Europe and Australia. This study is designed to assess objective response (OR) \[complete response (CR) or partial response (PR)\] in subjects with cutaneous manifestations of CTCL with a requirement for maintenance of such objective response for at least 28 days in subjects with stage IIB, III, and IVA CTCL. Additionally, this study will evaluate the safety and tolerability of CTCL subjects Stages IB, IIA, IIB, III, or IVA treated with oral forodesine.

Forodesine in the Treatment of Cutaneous T-Cell Lymphoma

Single Agent Phase II Study of Forodesine (BCX1777) in the Treatment of Cutaneous T-Cell Lymphoma

BioCryst Pharmaceuticals

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Forodesine in the Treatment of Cutaneous T-Cell Lymphoma	NCT00501735	Cutaneous T-cel...	Forodesine 200 ...	18 Years -	BioCryst Pharmaceuticals
Forodesine in the Treatment of Cutaneous T-Cell Lymphoma	NCT00501735	Cutaneous T-cel...	Forodesine 200 ...	18 Years -	BioCryst Pharmaceuticals

Spots Global Cancer Trial Database for forodesine 200 mg